Q3 2023 Results - Reimagining Medicine
Company overview
Financial review
Conclusions
Innovation: Pipeline overview
Financial performance
Cardiovascular
Immunology
Neuroscience
Ophthalmology
ganaplacide - Non-artemisinin plasmodium
falciparum inhibitor
NCT04546633 KALUMI (CKAF156A2203)
Indication
Malaria, uncomplicated
Phase 2
Phase
Patients
292
Primary
Outcome
Measures
Arms
Intervention
Target
Patients
PCR-corrected and uncorrected Adequate Clinical and Parasitological
Response (ACPR)
KAF156 and LUM-SDF QD (once daily) for 2 days in fasted condition
KAF156 and LUM-SDF QD (once daily) for 2 days in fed condition
Malaria patients 6 months to < 18 years old
Readout
Milestone(s)
Publication
2024
TBD
84 Investor Relations | Q3 2023 Results
Appendix
Innovation: Clinical trials
Oncology
Global Health
References
Abbreviations
Other
1 NOVARTIS | Reimagining MedicineView entire presentation